Search the Full Research Index

FDA's GSRS identifies the 5-amino-1-methylquinolinium ion as a distinct substance record, separate from its iodide and chloride salt forms.

The letter addresses 503B eligibility and manufacturing/compliance findings; it is not evidence of efficacy.

PubChem CID 950107 records the 5-amino-1-methylquinolinium ion as a defined chemical entity, distinct from its iodide and chloride salt forms.

5A1MQ treatment limited weight and fat-mass gain and improved glucose-related measures in mice, with sex-dependent effects. The paper remains preclinical and provides no basis for a human dosing or safety recommendation.

A mouse study found that NNMT inhibition combined with a lower-calorie diet reduced adiposity and changed the gut microbiome in diet-induced obese mice. Diet was a co-intervention, limiting attribution to NNMT inhibition alone.

An LC-MS/MS bioanalytical method characterized 5-amino-1-methylquinolinium exposure in rat plasma and urine. This is a bioanalytical method development study, not a safety or efficacy trial.

Obesity/metabolic pathway — Summarizes 5-amino-1MQ-treated mouse findings and NNMT obesity biology.

The study developed methylquinolinium NNMT inhibitors, including the 5-amino-1-methylquinolinium scaffold, and demonstrated anti-obesity effects in high-fat-diet mouse models. This establishes 5-Amino-1MQ as a small-molecule NNMT inhibitor, not a peptide.

Adipocyte and mouse studies — 5-amino-1MQ inhibited NNMT and reduced adiposity/metabolic markers in models.

Cell studies reported antiproliferative activity of 5-amino-1-methylquinolinium-related compounds in cervical-cancer (HeLa) cells. This is preclinical cell evidence and does not establish that 5-Amino-1MQ prevents or treats cancer in humans.

Preclinical studies evaluated NNMT inhibition in kidney-fibrosis models and reported reduced senescence or fibrosis markers. These models do not prove treatment of chronic kidney disease or other fibrotic conditions in humans.

L-alanyl-L-histidyl-L-lysine-Cu2+ (AHK-Cu) stimulated elongation of isolated human hair follicles ex vivo and proliferation of cultured dermal papilla cells. This was not a clinical treatment trial.

Broader peptide-copper-complex research reported hair-follicle stimulation in mice.

FDA guidance on distinguishing cosmetic from drug intended use: a product's intended use (as shown by claims) determines whether it is regulated as a cosmetic, a drug, or both, independent of ingredient identity. Shared reference for both AHK-Cu and SNAP-8.

PubChem records identify AHK-Cu (the copper complex of L-alanyl-L-histidyl-L-lysine) and AHK-Cu hydrochloride as distinct chemical substance records. A database identity record is not FDA approval or clinical validation.

FDA GSRS identifies ARA-290 and cibinetide as synonyms for the same 11-amino-acid peptide. FDA states that UNII availability does not imply regulatory review or approval.

Current registry record; a registry listing is not evidence of completed efficacy results.

Small phase 2 study evaluated ocular and systemic outcomes; it was exploratory and not definitive evidence of clinical efficacy.

Cibinetide increased corneal and cutaneous small-nerve-fiber abundance in patients with sarcoidosis-associated small-fiber loss. The findings support biological activity but do not constitute approval.

In type 2 diabetes with painful neuropathy, ARA-290 was associated with improvement in neuropathic symptoms and selected metabolic measures over a short trial. No major safety issue was identified, but larger confirmatory studies were required.

Clinical evaluation reported improvement in neuropathic-pain symptoms during ARA-290 treatment.

The registry documents clinical investigation of ARA-290 in sarcoidosis-associated neuropathy. Registration and completion do not imply FDA approval.

In patients with sarcoidosis-associated small-fiber neuropathy, 28 days of ARA-290 improved neuropathic symptoms and was associated with increased corneal nerve-fiber density. The trial was small and exploratory.

Official registry for the controlled type 2 diabetes study.

Pilot randomized data reported improvement in neuropathic symptoms and supported further evaluation.

ARA-290 was evaluated for tissue-protective effects in diabetic neuropathy models.

PubChem's Cibinetide compound record establishes the identity of the 11-amino-acid synthetic peptide derived from the three-dimensional structure of erythropoietin. Used for identity verification only, not efficacy evidence.

FDA identifies route-dependent immunogenicity, peptide-impurity, API-characterization, and insufficient safety-information concerns.

FDA found BPC-157 insufficiently characterized, found insufficient evidence of effectiveness for ulcerative colitis, and proposed that free base and acetate not be added to the 503A Bulks List.

The meeting was scheduled after the MitoCore research review date, so no final committee vote or post-meeting FDA action was available for this pack.

BPC-157 is prohibited at all times under the 2026 WADA list.

No adverse effects or measured biomarker changes were reported after two consecutive-day infusions.

Participants reported substantial symptom improvement on a Global Response Assessment after one procedure.

Most contacted patients reported pain improvement, but outcomes were nonstandardized and the intervention was mixed in four patients.

BPC-157 increased explant outgrowth, cell survival under oxidative stress, migration, spreading, and FAK/paxillin phosphorylation in the experimental systems.

A registered 2026 trial is designed to investigate BPC-157 for acute grade-II hamstring injury. Registration or recruitment status does not establish safety or effectiveness and should not be reported as a positive result.

A 2026 review of BPC-157 musculoskeletal evidence found that human clinical evidence remains limited to small, uncontrolled, or retrospective reports and does not establish that BPC-157 heals tendons, ligaments, muscle, or cartilage in humans.

Bremelanotide improved sexual desire and related distress on co-primary endpoints compared with placebo; effect sizes and discontinuation from adverse events require context.

Intranasal PT-141 produced erectile responses in this early controlled study.

-20.4% weight change vs. -3.0% placebo (p<0.001); GI adverse events 79.6% vs. 39.9% placebo.

Novo Nordisk states that cagrilintide monotherapy is being advanced in the RENEW phase 3 program and cites REDEFINE 1 monotherapy data. This supports late-stage investigational status as of the research date, not approval.

Confirms a New Drug Application for CagriSema (cagrilintide + semaglutide) was submitted to the FDA in December 2025; decision expected in 2026. Cagrilintide is not FDA-approved as a standalone product.

Combination (CagriSema) HbA1c -2.2pp, weight -15.6% vs. cagrilintide alone -0.9pp/-8.1%.